standard f200 analyser tf, , , equipement médical
sd biosensor, inc. - analyser tf -
blincyto poudre pour solution
amgen canada inc - blinatumomab - poudre pour solution - 38.5mcg - blinatumomab 38.5mcg - antineoplastic agents
leqvio solution
novartis pharmaceuticals canada inc - inclisiran (inclisiran sodique) - solution - 284mg - inclisiran (inclisiran sodique) 284mg
blincyto
amgen europe b.v. - blinatumomab - cellule précurseur leucémie lymphoblastique - lymphome - agents antinéoplasiques - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
pemetrexed b-medical 500 mg sol. perf. (pdr., à diluer) i.v. flac.
b-medical b.v. - pémétrexed disodique 604 mg - eq. pémétrexed 500 mg - poudre pour solution à diluer pour perfusion - 500 mg - pémétrexed disodique 604 mg - pemetrexed
labetalol b-medical 5 mg/ml sol. inj. i.v. amp.
b-medical b.v. - chlorhydrate de labétalol 5 mg/ml - solution injectable - 5 mg/ml - chlorhydrate de labétalol 5 mg/ml - labetalol
increlex solution
ipsen biopharmaceuticals canada inc - mécasermine - solution - 40mg - mécasermine 40mg - somatotropin agonists*
ciprofloxacine medical technologies 400 mg/200 ml, solution pour perfusion
medical technologies limited - ciprofloxacine - solution - 400 mg - composition pour un flacon de 200 ml > ciprofloxacine : 400 mg . sous forme de : lactate de ciprofloxacine - fluoroquinolone
ciprofloxacine medical technologies 200 mg/100 ml, solution pour perfusion
medical technologies limited - ciprofloxacine - solution - 200 mg - composition pour un flacon de 100 ml > ciprofloxacine : 200 mg . sous forme de : lactate de ciprofloxacine - fluoroquinolone
ciprofloxacine medical technologies 400 mg/200 ml, solution pour perfusion en poche
medical technologies limited - ciprofloxacine - solution - 400 mg - composition pour une poche de 200 ml > ciprofloxacine : 400 mg . sous forme de : lactate de ciprofloxacine - fluoroquinolone